EQT Life Sciences Invests in Innovative Sleep Apnea Therapy
EQT Life Sciences is excited to share its latest investment in Mosanna Therapeutics, securing a significant Series A funding round of USD 80 million. This financial boost is geared towards advancing Mosanna's unique nasal spray therapy, designed specifically to tackle obstructive sleep apnea (OSA) through comprehensive Phase 2 clinical trials.
The Appointment of New Leadership
As part of this promising venture, Biotech veteran David Weber has taken the reins as the new CEO of Mosanna. His extensive background in biotech and proven leadership will help steer the company through its clinical development phase, which is crucial for the nascent therapy.
Addressing a Global Health Challenge
Obstructive sleep apnea is a pervasive condition affecting approximately 1 billion individuals around the world, many of whom remain undiagnosed and without effective treatment options. The implications of untreated OSA are serious, including risks of hypertension, cardiovascular complications, stroke, and even depression. Many patients often suffer through the day feeling excessively sleepy, exacerbating issues such as workplace accidents.
Revolutionizing Treatment Approaches
Mosanna Therapeutics aims to revolutionize the treatment of sleep apnea by introducing its product, MOS118, an innovative nasal spray. Unlike traditional mechanical methods which can be cumbersome and uncomfortable, MOS118 is completely non-invasive and aims to restore natural airway reflexes that often diminish during sleep. This new approach not only makes treatment more comfortable but potentially more effective for a population that has faced long-standing neglect in terms of adequate care.
Funding Directions and Development Pipeline
The Series A funds are strategically allocated to facilitate the advancement of MOS118 through critical Phase 2 clinical trials. Additionally, the financing will support the expansion of Mosanna's development pipeline, paving the way for future innovations in sleep apnea treatment and beyond.
Expert Insights on Mosanna’s Vision
Daniela Begolo, Ph.D., Managing Director at EQT Life Sciences, expressed enthusiasm about Mosanna's innovative approach: "What sets Mosanna apart is its fundamentally different approach to sleep apnea, treating it as a neurological and muscular dysfunction rather than a purely mechanical issue." This insight highlights how MOS118 may not only offer a new treatment but also shift how we understand and approach OSA.
Furthermore, Dr. Weber stated, "Mosanna is taking a truly transformational approach to sleep apnea treatment – offering a non-invasive, non-mechanical solution designed to seamlessly fit into daily life. With this funding, we're accelerating development to bring this groundbreaking treatment to patients who desperately need better options." His leadership promises to drive the mission forward as Mosanna aims to combat sleep apnea effectively.
Contact Information
If you wish to get more information regarding Mosanna Therapeutics or their groundbreaking work, you can reach the EQT Press Office.
Frequently Asked Questions
What is the significance of the USD 80 million funding for Mosanna?
The funding will allow Mosanna to progress its nasal spray therapy through Phase 2 clinical trials, potentially leading to a new treatment option for sleep apnea.
Who is leading Mosanna Therapeutics now?
David Weber has been appointed as the new CEO to guide the company's clinical development efforts.
What makes MOS118 different from existing sleep apnea treatments?
MOS118 is a nasal spray that aims to restore natural airway reflexes rather than relying on mechanical devices, providing a more comfortable treatment option.
How prevalent is obstructive sleep apnea globally?
Obstructive sleep apnea affects around 1 billion people worldwide, with many remaining undiagnosed and untreated.
What are the health risks associated with untreated sleep apnea?
Untreated OSA can lead to serious health issues such as hypertension, cardiovascular disease, and increased risk of stroke and depression.
